Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

Qinglin Li

State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics

Zulei Shao

Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, China; Zulei Shao, MM, Postgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, China;Xiaoling Xu, MD, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; and Weimin Mao, MD, >Key Laboratory of Diagnosis and Treatment Technology Research for Thoracic Tumors of Zhejiang, Cancer Hospital of Zhejiang Province, Hangzhou, China

Xiaoling Xu

Zhejiang Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University

Weimin Mao

Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, China